The journal of headache and pain · 2019
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Favoni Valentina, Giani Luca, Al-Hassany Linda, Asioli Gian Maria, Butera Calogera, de Boer Irene, Guglielmetti Martina, Koniari Chrysoula, Mavridis Theodoros, Vaikjärv Marge, Verhagen Iris, Verzina Angela, Zick Bart, Martelletti Paolo, Sacco Simona, European Headache Federation School of Advanced Studies (EHF-SAS)
Аннотация
Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with migraine. CGRP and its receptors are distributed not only in the central and peripheral nervous system but also in the cardiovascular system, both in blood vessels and in the heart. We reviewed the current evidence on the role of CGRP in the cardiovascular system in order to understand the possible short- and long-term effect of CGRP blockade with monoclonal antibodies in migraineurs.In physiological conditions, CGRP has important vasodilating effects and is thought to protect organs from ischemia. Despite the aforementioned cardiovascular implication, preventive treatment with CGRP antibodies has shown no relevant cardiovascular side effects. Results from long-term trials and from real life are now needed.